This is the authors' abstract. We don't add key points for this paper.
Overall survival (OS) is the most meaningful endpoint in clinical trials. However, owing to their limitations, surrogate endpoints are commonly used and validation studies are required to assess their reliability. Analysis of phase III randomized controlled trials (RCTs) of advanced gastroesophageal cancer (AGC) with > 100 patients, correlation coefficients ( r ), and determination coefficients ( R² ) between OS and surrogates were evaluated through meta-analyses. Progression-free survival (PFS), time to progression (TTP), and objective response rate (ORR) were examined to determine their correlations with OS. Analysis of 65 phase III RCTs (29,766 subjects) showed a moderate correlation between PFS/TTP and OS ( r = 0.77, R² = 0.59), while ORR correlation was low ( r = 0.56, R² = 0.31). Excluding immunotherapy trials improved the PFS/TTP and OS correlations ( r = 0.83, R² = 0.70). These findings suggest the potential use of PFS/TTP in AGC phase III investigations, disregarding the use of ORR as a surrogate endpoint. • Moderate correlation between progression-free survival and overall survival. • A weak association between objective response rate and overall survival. • The surrogate threshold effect predicts survival treatment effects in future trials. • Strong correlation in first-line settings, chemotherapy, and anti-HER2 therapy trials. • The effect of immunotherapy on survival may be better captured by other endpoints.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Rodríguez et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: